Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650648 · ClinicalTrials.gov registry record · Phase 1
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT02650648: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02650648 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650648, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for neuroblastoma. NK cells are a type of white blood cell. Funding Source- FDA OOPD
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL NK cells
- BIOLOGICAL hu3F8
- DRUG rIL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2016-01-05 |
| Est. Completion | 2025-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02650648
The ClinicalTrials.gov registry entry for NCT02650648 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT02650648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02650648 about?
NCT02650648 is a clinical study titled "Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma". This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for neuroblastoma. NK cells are a type of white blood cell. Funding Sourc...
What is the current status of trial NCT02650648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2016-01-05. Estimated completion is 2025-07-28.
What interventions are being tested in trial NCT02650648?
The interventions under investigation include: cyclophosphamide (DRUG), NK cells (BIOLOGICAL), hu3F8 (BIOLOGICAL), rIL-2 (DRUG).
Who is sponsoring clinical trial NCT02650648?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.